Floatz logo

Brentuximab Vedotin

Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma

Northwestern Universityantibody_drug_conjugatePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Shandong Provincial Hospital
Phase 4BBB
ETOPOSIDE
Shandong Provincial Hospital
Phase 4BBB
(+)-VINCRISTINE
Shandong Provincial Hospital
Phase 4BBB
Ifosfamide
Shandong Provincial Hospital
Phase 4BB
Inno-206
Ruijin Hospital
Phase 4BB

View all 16 →

Same molecule, other indications

Brentuximab Vedotin is also rated in:

T-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
anaplastic large cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →